248 related articles for article (PubMed ID: 35128843)
1. Local Release of TGF-β Inhibitor Modulates Tumor-Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and Immunotherapy.
Peng H; Shen J; Long X; Zhou X; Zhang J; Xu X; Huang T; Xu H; Sun S; Li C; Lei P; Wu H; Zhao J
Adv Sci (Weinh); 2022 Apr; 9(10):e2105240. PubMed ID: 35128843
[TBL] [Abstract][Full Text] [Related]
2. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model.
Narayanan JSS; Ray P; Hayashi T; Whisenant TC; Vicente D; Carson DA; Miller AM; Schoenberger SP; White RR
Cancer Immunol Res; 2019 Oct; 7(10):1714-1726. PubMed ID: 31409607
[TBL] [Abstract][Full Text] [Related]
3. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer.
Zhao J; Wen X; Tian L; Li T; Xu C; Wen X; Melancon MP; Gupta S; Shen B; Peng W; Li C
Nat Commun; 2019 Feb; 10(1):899. PubMed ID: 30796212
[TBL] [Abstract][Full Text] [Related]
4. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
5. Irreversible Electroporation-Induced Inflammation Facilitates Neutrophil-Mediated Drug Delivery to Enhance Pancreatic Cancer Therapy.
Huang T; Wen X; Liang Y; Liu X; Zhao J; Long X
Mol Pharm; 2024 Apr; 21(4):1998-2011. PubMed ID: 38412284
[TBL] [Abstract][Full Text] [Related]
6. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
[TBL] [Abstract][Full Text] [Related]
7. Irreversible electroporation promotes a pro-inflammatory tumor microenvironment and anti-tumor immunity in a mouse pancreatic cancer model.
Imran KM; Brock RM; Beitel-White N; Powar M; Orr K; Aycock KN; Alinezhadbalalami N; Salameh ZS; Eversole P; Tintera B; Markov Madanick J; Hendricks-Wenger A; Coutermarsh-Ott S; Davalos RV; Allen IC
Front Immunol; 2024; 15():1352821. PubMed ID: 38711517
[TBL] [Abstract][Full Text] [Related]
8. Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer.
Yang J; Eresen A; Shangguan J; Ma Q; Yaghmai V; Zhang Z
Oncoimmunology; 2021 Feb; 10(1):1875638. PubMed ID: 33643692
[TBL] [Abstract][Full Text] [Related]
9. Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy.
Yu B; Zhang W; Kwak K; Choi H; Kim DH
ACS Appl Mater Interfaces; 2020 Dec; 12(49):54415-54425. PubMed ID: 33237729
[TBL] [Abstract][Full Text] [Related]
10. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
[TBL] [Abstract][Full Text] [Related]
11. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.
Yu Q; Tang X; Zhao W; Qiu Y; He J; Wan D; Li J; Wang X; He X; Liu Y; Li M; Zhang Z; He Q
Acta Biomater; 2021 Oct; 133():244-256. PubMed ID: 34000465
[TBL] [Abstract][Full Text] [Related]
12. Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells.
Burbach BJ; O'Flanagan SD; Shao Q; Young KM; Slaughter JR; Rollins MR; Street TJL; Granger VE; Beura LK; Azarin SM; Ramadhyani S; Forsyth BR; Bischof JC; Shimizu Y
Nat Commun; 2021 Jun; 12(1):3862. PubMed ID: 34162858
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.
O'Neill C; Hayat T; Hamm J; Healey M; Zheng Q; Li Y; Martin RCG
Surgery; 2020 Oct; 168(4):610-616. PubMed ID: 32631655
[TBL] [Abstract][Full Text] [Related]
15. Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma.
Woeste MR; Shrestha R; Geller AE; Li S; Montoya-Durango D; Ding C; Hu X; Li H; Puckett A; Mitchell RA; Hayat T; Tan M; Li Y; McMasters KM; Martin RCG; Yan J
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072351
[TBL] [Abstract][Full Text] [Related]
16. Transforming Growth Factor-β1 in Cancer Immunology: Opportunities for Immunotherapy.
Villar VH; Subotički T; Đikić D; Mitrović-Ajtić O; Simon F; Santibanez JF
Adv Exp Med Biol; 2023; 1408():309-328. PubMed ID: 37093435
[TBL] [Abstract][Full Text] [Related]
17. Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors.
Zhang N; Li Z; Han X; Zhu Z; Li Z; Zhao Y; Liu Z; Lv Y
Front Immunol; 2021; 12():811726. PubMed ID: 35069599
[TBL] [Abstract][Full Text] [Related]
18. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.
Fridlender ZG; Sun J; Kim S; Kapoor V; Cheng G; Ling L; Worthen GS; Albelda SM
Cancer Cell; 2009 Sep; 16(3):183-94. PubMed ID: 19732719
[TBL] [Abstract][Full Text] [Related]
19. Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Groeneveldt C; van Ginkel JQ; Kinderman P; Sluijter M; Griffioen L; Labrie C; van den Wollenberg DJM; Hoeben RC; van der Burg SH; Ten Dijke P; Hawinkels LJAC; van Hall T; van Montfoort N
Cancer Res Commun; 2023 Feb; 3(2):325-337. PubMed ID: 36860656
[TBL] [Abstract][Full Text] [Related]
20. Exploration of Novel Pathways Underlying Irreversible Electroporation Induced Anti-Tumor Immunity in Pancreatic Cancer.
Imran KM; Nagai-Singer MA; Brock RM; Alinezhadbalalami N; Davalos RV; Allen IC
Front Oncol; 2022; 12():853779. PubMed ID: 35372046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
